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Abstract
Background: Adoptive T cell therapy involving the use of ex vivo generated antigen-specific cytotoxic T lymphocytes
provides a promising approach to immunotherapy. It has become increasingly apparent that anti-tumor efficacy using
adoptively transferred T cells is linked to their duration of in vivo persistence and can only be achieved when combined with
some form of pre-infusion patient conditioning regimen. An optimal conditioning regimen that provides a positive benefit
without serious toxicities has yet to be defined. We have established a unique clinical model that allows for evaluation of a
given conditioning regimen on adoptively transferred T cells in humans. In this first-in-human study (FHCRC #1796), we
evaluate the use of fludarabine, an FDA-approved reagent with predictable lymphodepleting kinetics and duration of
action, as a conditioning regimen that promotes homeostatic upregulation of cytokines and growth signals contributing to
in vivo T cell persistence.
Methods/Findings: We conducted a phase I study in patients with refractory metastatic melanoma. Patients received two
infusions of a single tumor-reactive antigen-specific CTL clone expanded to 10
10/m
2; the first infusion was given without
fludarabine conditioning, and the second CTL infusion was given after a course of fludarabine (25 mg/m
2/day65 days). This
design permits intra-patient comparison of in vivo T cell persistence pre- and post-fludarabine. Nineteen CTL infusions were
administered to ten patients. No serious toxicities were observed. Three of nine evaluable patients experienced minor
response or stable disease for periods of 5.8–11.0 months with two additional patients demonstrating delayed disease
stabilization. The median overall survival in this heavily pre-treated population was 9.7 months. Fludarabine led to a 2.9 fold
improvement in the in vivo persistence of transferred CTL clones from a median of 4.5 days (range 0–38+) to 13.0 days
(range 2–63+)( p ,0.05). Fludarabine lymphodepletion increased plasma levels of the homeostatic cytokines IL-7 and IL-15.
Surprisingly, fludarabine also increased the relative percentage of CD4+ T cells expressing the regulatory protein Foxp3.
Conclusions/Significance: Lymphodepletion with fludarabine enhances transferred T cell persistence but suggest that
additional improvements to optimize T cell survival and address regulatory T cells are critical in providing anti-tumor efficacy.
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Introduction
Adoptive T cell therapy involves the ex vivo isolation and
expansion of tumor-reactive T lymphocytes for patient infusion
and has proven to be a promising approach to cancer
immunotherapy. Tumor-reactive effector cells of desired specific-
ity and phenotype can be identified in vitro, selected based on
expression of a high affinity receptor and specific surface markers
and expanded to several billion in number. The use of a well-
defined, uniform population of T cell clones facilitates in vivo
tracking and provides a means of rigorously evaluating the
influence of extrinsic immunomodulatory factors on the anti-
tumor T cell response.
In phase I clinical trials, transfer of antigen specific CD8+ T
(CTL) cells for the treatment of patients with metastatic melanoma
led to encouraging clinical responses[1,2]. Results using CD8+
(CTL) clones targeting MART-1 and gp100 in conjunction with
low doses of IL-2 demonstrated that infused clones can be detected
in appreciable numbers, traffic to tumor sites, and result in tumor
regression[1]. However, in these studies, adoptively transferred
CTL experienced a limited period of in vivo persistence and the
duration of in vivo persistence has been closely linked to the clinical
response[3].
In murine models, pre-infusion conditioning (in the form of
chemotherapy or radiation-induced lymphodepletion) may extend
the survival and function of transferred T cell in vivo through a
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proliferative cytokines such as IL-7 and IL-15[4,5], depletion of
inhibitory regulatory T cells[6,7], or potentially the creation of
immunologic ‘‘space’’ . Prior host lymphodepletion has been
shown in murine models to be important for the anti-tumor
efficacy of adoptive cellular therapy[8,9].
In a recent study reported by investigators at NIH[10], adoptive
transfer of autologous tumor infiltrating lymphocytes following
immunodepletion with high-dose cyclophosphamide and fludara-
bine resulted in tumor regression accompanied by in vivo T cell
expansion and in some cases, virtual replacement of the entire
peripheral T cell repertoire with the infused clone. It is not clear,
however, that such a skewed reconstitution of the immune system
is required for optimizing T cell persistence nor that such a
profound level of immuno-depletion which was accompanied by
serious and potentially life-threatening toxicities, is essential. We
postulated that induction of a relative lymphopenia without
attendant serious toxicities may be sufficient to upregulate in vivo
homeostatic cytokines to the benefit of transferred T cells.
Fludarabine is a purine analog which induces lymphopenia
when administered in a standard five day course. It reduces the
reduces the average CD4 counts by ,80%, with sustained
lymphodepletion for approximately 4 weeks. While some risk
associated with lymphopenia is observed in patients receiving
multiple cycles of fludarabine therapy, the frequency and severity
of infectious complications is significantly less and the period of
lymphopenia is well-defined in patients receiving a single five-day
course of fludarabine[11]. While fludarabine has significant effects
on hematologic malignancies, it has no anti-tumor effect on solid
tumors such as melanoma[12].
To evaluate the influence of fludarabine lymphodepletion, we
established a unique clinical model that allows for rigorous
evaluation of the influence of a given conditioning regimen on T
cell therapy in humans. A single tumor-reactive antigen-specific
CTL clone expanded to 10
10 cells/m
2 is used for both a first
infusion given to patients without conditioning, and then, for a
second infusion, following patient conditioning. This strategy allows
intra-patient comparisons and eliminates any confounding vari-
ability associated with disparate behavior among T cell clones in
different recipients. In this study, we evaluate the use of
fludarabine, a lymphodepleting agent with predictable kinetics
and duration of action, as a conditioning regimen to enhance the
in vivo persistence of transferred T cells. We report the results of a
phase I study, Fred Hutchison Cancer Research Center (FHCRC)
Protocol #1796, in ten patients with refractory, metastatic
melanoma receiving autologous CD8+ T cell clones targeting a
melanoma-associated antigen (MART-1, gp100, or tyrosinase),
without and with prior fludarabine lymphodepletion.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. FHCRC protocol #1796 received
prior approval by the institutional review board at the Fred
Hutchison Cancer Research Center. All patients provided written
informed consent for the collection of samples and subsequent
analysis.
Generation of antigen specific CD8+ T cell clones
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1, IRB
approval S1, Flow Diagram S1, and Protocol S1. Peripheral blood
mononuclear cells (PBMCs) were obtained by leukopheresis and
antigen-specific CD8+ T lymphocytes were generated using
autologous dendritic cells pulsed with the HLA-A2 restricted
peptide epitopes MART-1 (M27:AAGIGILTV), gp100(G154:
KTWGQYWQV), or tyrosinase (T368: YMDGTMSQV
(40 ug/ml first stimulation, 10 ug/ml subsequent stimulations).
After three cycles of stimulation at weekly intervals, T cells were
cloned by limiting dilution and expanded for in vitro testing. CTL
clones demonstrating rapid in vitro growth and specific lysis of
antigen-positive tumor targets in a Cr
51 release assay were selected
for expansion. Clones were expanded in a 14 day cycles using
anti-CD3 antibody (OKT3) at 30 ng/ml, irradiated allogeneic
PBMCs at 10
6/ml, irradiated allogeneic lymphoblastoid cell lines
(2610
5/ml), and serial IL-2 at 50 U/ml every 2–3 days as
described previously[1]. All clones demonstrated Class I MHC
restricted antigen-specific cytolytic activity, characterized as
CD3+CD8+CD42, and subsequently cryopreserved. Clones were
thawed and lot released for intravenous infusion after demon-
strating viability .90%, cytolytic ability against A2+ targets, and
sterility testing.
Adoptive T cell therapy
Ten patients were underwent treatment in a phase I study of
adoptive T cell therapy. The procotol was open for recruitment
from May 2003 through June 2006. All patients met the following
entry criteria: histopathologic diagnosis of metastatic (stage IV)
melanoma expressing antigens Mart-1, gp100, or tyrosinase by
immunohistochemistry, HLA-A0201+, age,75, well-controlled
CNS disease or absence of CNS disease, and no clinically
significant cardiac, hepatic, renal, or pulmonary dysfunction. All
patients had measurable disease refractory to standard or
investigational treatments. 38 patients were initially screened and
17 patients met entry criteria for study (21 patients excluded were
non-HLA02). Subsequently 6 patients were excluded for meta-
static progressive disease in the brain. We were unable to generate
T cells for one of the patients meeting entry criteria. Patients
underwent leukapheresis before initiating other therapies in order
that T cell clones could be generated in vitro and cryopreserved
until needed. Antigen specific T cell infusions were administered at
10
10 cells/m
2 intravenously for both infusion#1 and #2 according
to the study schema in Fig. 1. Two T cell infusions for each
patient were planned. For a given individual patient, CTL
Infusion #1 and #2 contained the same cryopreserved CTL
clone. The initial four patients received T cell infusions without
IL-2 supplementation. In the absence of any serious toxicity, the
last six patients received very low-dose IL-2 at 2.5610
5 U/m
2
twice-daily s.c. for 14 days following each T cell infusion as a
source of helper support. The dose of IL-2 used is sufficient to
saturate the high-affinity IL-2 receptor in vivo, and, when
administered alone, has no anti-melanoma effect and minimal
toxicity[13]. Twenty-one days after the first T cell infusion,
patients received fludarabine conditioning at 25 mg/m
2/day
consecutively for five days. Two days following the last dose of
fludarabine, a second infusion of T cells was administered. In
previous studies[1], we have shown that transferred CTLs persist
for less than 7 and 17 days, without and with IL-2, respectively;
therefore by 21 days, sufficient time will have elapsed so that T
cells from the first infusion could be adequately assessed for in vivo
persistence before the second infusion. Clinical trial data was
analyzed by HW and CY, and reviewed by all authors.
Clinical Evaluation
Patients were monitored for toxicities based upon Common
Toxicity Criteria v3.0[14]. Tumor measurements were obtained
four weeks after the second T cell infusion and every two months
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RECIST criteria[15] with the additional criterion of Minor
response, which is considered a decrease in the sum of target lesion
diameters between 20–30%, insufficient to qualify for Partial
response (30% decrease in the sum of the diameters). All patients
were followed clinically and radiographically until death.
Evaluation of in vivo persistence
Tetramers were generated according to the protocol of
Altman[16] and described previously[1]. To evaluate the in vivo
persistence of T cells in peripheral blood, PBMCs were prepared
from samples drawn on day 0 (pre-infusion), and days 1, 3, 7, and
weekly until at least day 28. Phlebotomy maybe delayed for one
day due to logistical or technical reasons. After completion of the
study, PBMC samples were thawed and analyzed simultaneously
by staining with peptide-MHC tetramer-APC or PE (25–50 ug/
ml), anti-CD8-PE-Cy7, anti-CD3PE or APC, and ‘‘dump’’
antibodies. Flow cytometric analyses were carried out on a
minimum of 50,000 cells. The frequency of antigen-specific CTL
is presented as the fraction of tetramer
+CD8
+ lymphocytes divided
by the total number of CD8
+ cells. The duration of persistence is
defined as the duration of an increase in tetramer
+ CTL frequency
at least two fold greater than the frequency in the pre-T cell
infusion sample. All patient samples were tested in duplicate. This
method detects with high specificity a frequency of antigen-specific
T cells as low as 0.1% CD8+ cells.
Intracellular Foxp3 staining
The human antibodies APC and PE-conjugated anti-CD3,
FITC and PE-Cy7 conjugated anti-CD8, FITC-conjugated anti-
CD4, and FITC-conjugated anti-CD14/16/19 ‘‘dump antibod-
ies,’’ were obtained from BD biosciences. PE-conjugated anti-
Foxp3 (Ebiosciences) and intracellular staining was performed
according to the manufacturer’s instructions and modified as
follows: 5610
5 cells were stained for surface markers for
30 minutes at 22uC, fixed for 30 minutes with 16 Fix/Perm
buffer. After three washes, cells were permealized in Perm buffer
with DNase I (100 U) for 30 minutes followed by three washes.
Then cells were blocked with 2% fetal calf serum and stained with
PE-conjugated anti-human foxp3 (Ebioscience, clone PCH101).
The frequency of Foxp3+ CD4+ cells is presented as a fraction of
the total number of CD4+ cells after gating on CD3+ cells.
Plasma cytokine levels
Plasma samples were drawn prior to the first T cell infusion,
immediately prior to the second T cell infusion (corresponding to
48 hours post-fludarabine), and timepoints 7, 14, and 21 days
after the second T cell infusion. Plasma samples were frozen,
thawed, and analyzed simultaneously by the Cytokine Analysis
Facility at the FHCRC for IL-7, IL-15, and in selected cases IL-2
by sandwich ELISA. This assay was capable of detecting at least
0.4 pg/ml of IL-7 or IL-15.
Elispot analysis
Human IFN-c ELISPOT assays were performed as previously
described[17] using capture and detection antibodies D1K and 7-
B6-1 (10 mg/ml; Mabtech and Nacka), respectively. Autologous
monocytes were pulsed at 10 ug/ml with the relevant peptide in
parallel with an irrelevant peptide for each sample. Cryopreserved
PBMCs from serial timepoint samples were plated at 1610
5 cells
per well and co-cultivated with stimulator monocytes for 24 h.
The plates were analyzed using an automated ImmunoSpot
Analyzer (Cellular Technology). Results are presented as the mean
number of spot forming cells/10
5 PBMCs.
Statistical analysis
Significance of variation between two groups was evaluated
using a two-tailed paired t test, with p,0.05 considered
significant(for Cytokine comparisons, CD4 levels, and Foxp3
analysis). The Wilcoxon signed rank test was used to compare T
cell persistence before and after fludarabine. Linear regression for
best-fit analysis, paired t tests, and Wilcoxon signed rank test were
performed on a GraphPad Prism
TM 4.0a software.
Results
Patient Demographics
Nine of the patients presented with cutaneous melanoma and
one with anal mucosal melanoma (Table 1). Eight of ten patients
had multiple sites of metastatic disease. Two patients had
previously received stereotactic brain irradiation and at the time
of study entry had no evidence of recurring CNS disease. All
patients had failed previous therapy with conventional treatments
for metastatic melanoma (IFN, high dose IL-2, biochemotherapy,
or chemotherapy). Three patients had previously been treated on
Figure 1. Treatment schema. Patients #1–4 received gp100, MART-1, or tyrosinase specific CD8+ T cell (CTL) infusions and fludarabine
conditioning without IL-2. Patients #5–10 received very low dose IL-2 at 2.5610
5 s.c. bid for 14 days following each T cell infusion. Patients were
evaluated for response four weeks after the CTL infusion #2 and every 2 months thereafter.
doi:10.1371/journal.pone.0004749.g001
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targeting MART-1 and gp100 antigens[1].
Toxicities associated with Adoptive T cell therapy using
melanoma-associated antigen specific CD8+ T cells and
fludarabine conditioning
Patients were monitored for signs or symptoms of toxicity
including autoimmune disorders since Mart-1, gp100, or tyrosi-
nase are found in normal melanocytes and uveal tissue. No grade
III or IV toxicity was observed[14]. All patients experienced
fevers, mild nausea, and fatigue consistent with cytokine release
syndrome beginning soon after T cell infusion and remitting
spontaneously within 48 hours. One patient, #8, developed an
erythematous rash around pigmented areas of skin on day 4 after
his first infusion of MART-1 specific T cells. A skin biopsy
revealed an intense lymphocytic infiltrate and immune mediated
destruction of nevomelanocytes (data not shown) consistent with
our previous description of T cell mediated vitiligo[18]. Patient #7
received steroids before his second infusion for progression of CNS
disease; his second T cell infusion was not given. Patient #3
developed a grade II pneumonia six weeks after his fludarabine
during a period of prolonged lymphopenia and was treated
successfully with oral antibiotics.
Clinical Responses
All patients at the time of T cell infusion had progressive
metastatic disease. One patient received only one infusion of T
cells. Of the nine patients who were able to receive both planned
infusions, disease stabilization was observed in two patients for a
period of 5.8 and 7.0 months, and one minor pulmonary response
with disease progression at 11.0 months (Table 2). All other
patients experienced progressive disease. Median progression free
survival and overall survival was 2.1 and 9.7 months, respectively.
Curiously, two patients (patients #5 and #8), whose disease
Table 1. Patient Characteristics.
Pt Age Melanoma Previous Therapy* Disease sites
{ LDH Stage
1 48 cutaneous Melacine, Chemotherapy Bone, AD, LN, DU q M1c
2 53 cutaneous Biochemotherapy, ACT, XRT Bone, SQ, LN q M1c
3 49 cutaneous Biochemotherapy, IL-2, IFN LU, LN, PV, SQ normal M1c
4 71 cutaneous Melacine, IFN, ACT LU, spleen normal M1c
5 56 cutaneous IL-2 LU normal M1b
6 59 anal Biochemotherapy LU normal M1b
7 56 cutaneous IL-2, brain XRT Brain, AD, DU normal M1c
8 36 cutaneous IL-2, IFN, ACT LU, LN q M1c
9 67 cutaneous Chemotherapy, IFN, brain XRT Brain, LU, Liver normal M1c
10 28 cutaneous Chemotherapy, XRT LU, LN normal M1b
Staging per AJCC staging criteria (M1b metastasis to lungs, M1c metastasis to other visceral sites or elevated LDH).
*ACT, adoptive cellular therapy; XRT, radiation.
{AD, adrenal; DU, duodenal; LN, lymph node; LU, lung; PV, pelvic.
doi:10.1371/journal.pone.0004749.t001
Table 2. T cell persistence (Tp) in vivo as determined by tetramer analysis.
Pt
Antigen
target IL-2
INF#1
Tp (days)
INF#1 peak
%tet/CD8
INF#2T p
(days)
INF#2 peak
%tet/CD8 Toxicity* Response
{
PFS
(days)
OS
(days)
1 Tyrosinase No 5 0.29 13 0.40 F PD 51 124
2 Gp100 No 4 0.11 6 0.18 F PD 60 71
3 Mart-1 No 3 0.31 13 1.39 F, PNA MR 330 535
4 Mart-1 No 5 0.84 27 2.32 F PD 56 97
5 Tyrosinase Yes 0 0.13 12 3.81 F PD 73 412
6 Mart-1 Yes 6 0.20 6 5.25 F SD 175 278
7 Gp100 Yes 38+ 5.89 n/a n/a F, R PD n/a 96
8 Mart-1 Yes 24 7.98 63+ 13.9 F, R PD 63 351
9 Mart-1 Yes 0 0.088 2 0.26 F PD 51 304
10 Mart-1 Yes 0 0.087 20 3.19 F SD 209 313
Median 4.5 0.25% 13.0** 2.32% 63 291
Comparison of T cell persistence between first infusion (INF#1) and second infusion (INF#2) shows a 2.9 fold increase (**p=0.0078, Wilcoxon-signed rank). Patients #5
and #8 exhibited delayed disease stabilization.
*F, fever; PNA, pneumonia; R, rash.
{PD, progressive disease; SD, stable disease; MR, minor response.
OS, overall survival; PFS, progression free survival.
doi:10.1371/journal.pone.0004749.t002
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zation and had prolonged survival for 10.1 and 13.7 months after
the initial T cell therapy. Such delayed responses following a
period of apparent progression, have been observed following
other immunotherapeutic strategies, such as anti-CTLA-4 therapy
and may represent an early inflammatory response, followed by
delayed disease remission[19].
Fludarabine leads to a decrease in CD4 lymphocyte
count and increased plasma levels of homeostatically-
regulated cytokines
Median pre-infusion (baseline) absolute CD4+ cell count was
770/mm
3 (range 280–1350/mm
3). CD4 counts declined to a
median of 150 cells/mm
3 (50–220) after fludarabine and remained
below normal for at least four weeks (Fig. 2). Median CD4 count
at D+28 was 250/mm
3 (160–511), and in two cases remained
,500/mm
3 for up to 8 weeks after conditioning. As anticipated,
this period of relative CD4 lymphopenia was accompanied by an
elevation in IL-7 and IL-15 plasma levels (compared to baseline
pre-infusion levels). Analyses for homeostatic cytokines IL-7 and
IL-15 were obtained in serial plasma samples prior to the first T
cell infusion, just prior to the second T cell infusion, and weekly
thereafter. Median plasma IL-7 levels rose from undetectable
levels at baseline to 2.9 pg/ml (0–24.2) at day 0 of the second
infusion (p=0.053). Median plasma IL-15 levels rose from
undetectable levels at baseline to 5.5 pg/ml (0–8.9) at day 0 of
the second infusion (p,0.01).
Fludarabine lymphodepletion leads to a 3-fold increase
in the persistence of adoptively transferred T cells
The in vivo survival of transferred T cells was determined by
measuring the frequency of tetramer
+ CD8 T cells in peripheral
blood samples (see Table 2). The median in vivo persistence of
transferred T cells was 4.5 days (range 0–38+) after the first T cell
infusion and extended to 13.0 days (2–63+) after the second
infusion (p=0.0078, Wilcoxon signed rank). Overall, fludarabine
improved the in vivo persistence of transferred T cells by an average
of 2.9 fold. Tetramer
+ CTL frequency peaked on days 1–3 post-
infusion at a median of 0.41% (0.10–7.98) of CD8+ T cells after
the first infusion and increased to 2.32% (0.18–14.1) after the
second infusion. Three patients (Pt #5, 9, and 10) did not have an
appreciable presence of transferred T cells after the first infusion in
peripheral blood by our criteria, however, they clearly developed a
measurable and significant tetramer
+ population after fludarabine
conditioning and second infusion. Among the three patients who
had received therapy with CD8+ T cell clones on our previous T
cell trial, there was no evidence of a residual infused T cell
population at baseline. Patient #7 received only the first infusion,
yet tetramer
+ T cells were detectable at .2% of CD8+ T cells for
at least 38 days. In patient #8, the presence of tetramer
+
population was observable for at least 63 days at a level of .1%
of CD8 cells (Fig. 3).
Functional capacity of post-infusion CTL clones
We measured the functional capacity of adoptively transferred
CTL clones to produce IFN-c in response to in vitro antigen after T
cell infusion. Sufficient PBMCs at serial timepoints post-infusion
were available for functional analysis in six patients. Post-T cell
infusion samples demonstrated a measurable population of IFN-c
producing cells responding to the cognate epitope by the
ELISPOT assay (see example in Fig. 3A). The presence of these
IFN-c secreting cells paralleled the in vivo persistence of adoptive T
cell clones except for one patient receiving steroid therapy (see
below: patient#7). In general, approximately 30% of the infused
CTL clones identified in vivo by tetramer analysis were capable of
secreting IFN-c by ELISPOT analysis (adjusted for CD8+/PBMC
ratio). When these clones are tested in vitro under optimal
conditions, a comparable fraction (25 to 30%) of T cells are
producing IFN-c at any one time suggesting that the infused clones
retain functional responsiveness in vivo.
Patient #7 received high dose corticosteroids four days after his
first T cell infusion for a recurrent CNS metastasis (Fig. 3B). He
was immediately placed on high dose dexamethasone. While this
did not apparently affect the numeric persistence of the transferred
Mart-1 specific T cell clone, the in vivo effect of corticosteroids
clearly diminished the capacity of the CTL clone to produce IFN-
c in response to antigen stimulation.
Fludarabine lymphodepletion leads to a relative increase
in Foxp3+ Regulatory T cells during recovery
Following fludarbine lymphodepletion, the percentage of CD4+
cells expressing Foxp3 rose from a median pre-therapy level of
7.4% (range 0.5–11.8%), to 18.0% (11.9–26.6%) just prior to the
second T cell infusion (p,0.01), and remained elevated at 12.0%
(7.72–19.7%) on day 21 after the second infusion (p,0.01) (Fig. 4).
The first four patients on the protocol did not receive IL-2
supplementation. At Day 0 of the second T cell infusion, an
increase in fraction of Foxp3+ cells is observed for all patients.
However, by D+21, patients who did not receive exogenous IL-2
normalized the fraction of Foxp3+ cells to near baseline levels
while those who received IL-2 experienced persistently elevated
levels of Foxp3+/CD4+ ratio (trend at p=0.093) (Fig. 5).
Figure 2. Plasma levels of IL-7 and IL-15 were measured at serial timepoints pre- and post fludarabine conditioning. CTL infusion #2
(INF#2) is administered two days after the final dose of fludarabine. *p=0.053 comparing pre-fludarabine (pre) versus day of INF#2 (for IL-7) and
**p,0.01 for pre- versus day of INF#2 (for both IL-15 and absolute CD4 levels).
doi:10.1371/journal.pone.0004749.g002
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significantly following lymphodepletion, the absolute numbers of
Foxp3+CD4+ cells remained relatively unchanged. There was no
clear relationship between numeric or functional persistence of
transferred T cells and the degree of Foxp3+/CD4+ population
(p=0.59).
Limited results of functional analysis from post-infusion PBMC
samples of flow cytometry sorted CD4+CD127lo cells were
explored in two patients (see Fig. S1). CD127lo cells contain
the Foxp3 hi expressing subset and are readily flow-sorted [20].
Comparison of CD127lo and CD127hi cells from post-infusion
PBMC samples in a mixed lymphocyte reaction with autologous
responder and irradiated allogeneic stimulator cells demonstrate
that CD127lo cells suppress thymidine incorporation in a
proliferation assay by 36% in one patient and 18% in another
(sorted to responder ratio of 0.3:1, tested in duplicate) [20].
Discussion
Use of ex vivo generated antigen specific T cell clones permits
selection of a uniform population of well-defined cytotoxic T cell
clones for infusion with known in vitro functional performance
characteristics. In our previous studies, we have shown that
adoptively transferred antigen-specific CD8+ CTL clones are
detectable post-infusion, persist in the presence of IL-2 supple-
mentation, are able to traffic to tumor sites, and effect anti-tumor
responses[1]. In second generation studies, we capitalized on the
use of CTL clones in a two-infusion intra-patient schedule that
allows us to rigorously evaluate the influence of a given
intervention (in this case, a pre-infusion conditioning regimen)
on adoptively transferred T cells. In the present example,
fludarabine was used for its predictable kinetics, low toxicity and
capacity to elicit CD4 lymphopenia at a level we hypothesized to
be sufficient to induce upregulation of homeostatic cytokines and
reduction of inhibitory regulatory T cells, beneficial to transferred
T cell survival.
Our studies reveal that fludarabine mediated lymphodepletion
was modest (median CD4+ nadir ,150cells/ul), but sufficient for
the upregulation of detectable levels of homeostatic cytokines (IL-7
and IL-15) and enhancement in the duration of in vivo persistence
of transferred T cells by almost 3-fold. IL-15 is well described as a
homeostatic cytokine promoting CD8+ T cell survival and
proliferation[4,21]. It is not clear whether exogenous IL-2 is
critical in lymphodepleted setting, however, since the four patients
Figure 3. A. In vivo persistence of CTL clones as measured by tetramer+ CD8+ T cells from post-infusion, cryopreserved PBMCs. Superimposed are
the correlative IFN-c ELISPOT data. ELISPOT results are presented as the mean number of spot forming cells/10
5 PBMCs. Shown is patient #8 who
demonstrated prolonged persistence of Mart-127–35 specific CTL. B. In vivo persistence and ELIspot data for patient #7 who received only one
infusion of Gp100154–162 specific CTL clones. The long arrow indicates initiation of high dose dexamethasone (dex).
doi:10.1371/journal.pone.0004749.g003
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persistence (median Tp post-fludarabine 13 vs 12 days).
Transferred T cells after fludarabine conditioning were
detectable at high frequencies. In six patients, they comprised
.2% of the CD8+ compartment in the peripheral blood from
days 1–3 post-infusion. In two of the patients, (Patients 7 and 8),
they were present in .1% frequency of CD8+ cells at day 38 and
63 after infusion. In our previous study (1), the median persistence
of T cells in the presence of IL-2 was nearly 17 days compared to
4.5 days (without conditioning) and 13 days (post-fludarabine) in
this present study. In contrast to our previous study, in order to
administer identical T cells in the two infusions, T cells were
cryopreserved until needed and thawed prior to infusion. Although
viability of T cells immediately prior to infusion was excellent
(.90%), this process may have affected the ultimate survival and
proliferative ability of T cell clones.
This study was designed to reduce the interpatient variability by
examining T cell persistence before and after administration of
fludarabine. The median T cell persistence after the first infusion
was 4.5 days. Only one patient had any detectable level of
transferred T cells at the time of fludarabine adminstration (given
on days 21–25 after first T cell infusion). Fludarabine rapidly
resulted in lymphodepletion and elimination of any residual T cells
in that patient (#8). At the time of the second T cell infusion, none
of the T cells from the first infusion were detectable with tetramer
monitoring. However, one limitation of this study is that we
cannot fully rule out the possibility of a sub-detectable population
from the first T cell infusion involved in altering the immunologic
milieu for the second infusion. Because fludarabine rapidly and
effectively depletes 80–90% of endogenous T cells, a cross-over
effect from the first infusion is very unlikely.
Transferred T cell clones also remain functional after infusion,
capable of producing IFN-c in response to antigen specific
stimulation with one exception. One serendipitous result of using a
well-defined clonal T cell population for adoptive therapy, was a
dramatic in vivo demonstration of corticosteroid’s deleterious effects
upon the functional capacity but not survival of CD8+ T cells in a
patient who received high-dose dexamethasone shortly after his T
cell infusion. Activation of the glucocorticoid receptor on T cells is
known to selectively inhibit expression of IFN-c and other Th1
cytokines, possibly by direct interaction with the Th1-specific
transcription factor T-bet[22]. While this has been shown in vitro,
this example would be the first demonstration that corticosteroids
can modulate the functional capacity of adoptively transferred
human effector T cell clones in vivo, underlining the importance of
evaluating both numeric and functional persistence when tracking
T cells in vivo for efficacy and toxicity.
In addition to upregulating homeostatic cytokines, fludarabine
conditioning was postulated to reduce regulatory Foxp3+ CD4+
cells (Treg). Treg cells, characterized as CD4+/CD25hi/foxp3+ are
known to be expanded in a variety of hematologic[23]as well as
solid tumor malignancies[6,24,25]. Treatment of CLL patients with
fludarabine was associated with a decreased frequency of regulatory
CD4+CD25
hi cells[26]. However, in that disease, fludarabine has a
direct anti-tumor effect in CLL, and the decline of Treg population
maysimplyreflectasmallertumorburdenwiththerapy.Incontrast,
fludarabine has no direct anti-melanoma effect. We observed,
surprisingly, anincrease inthe proportion ofFoxp3+ cellswithinthe
recovering CD4+compartment after fludarabine lymphodepletion.
Thisis the firsttime fludarabine has beenshown to enhance Foxp3+
expressing cells. Treg cells may be more resistant to apoptosis[27]
and/or recover from lymphodepletion faster than their non-
regulatory counterparts. Peripheral expansion of CD4+CD25
hi
Treg in vivo is regulated by both IL-2 and lymphopenia[28]. Thus,
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PLoS ONE | www.plosone.org 7 March 2009 | Volume 4 | Issue 3 | e4749there is concern regarding the growth enhancing effect of IL-2
administration during lymphopenia. Our data showing protracted
elevation of the Treg population in the presence of IL-2 and
lymphodepletion would support this contention.
Furthermore, there are safety concerns regarding fludarabine
when combined with other severe lymphodepleting modalities.
Fludarabine may contribute to a number of serious complications
observed in other studies[29] including opportunistic infections,
cortical blindness, and prolonged immunosuppression, the latter
ultimately being counterproductive by inhibiting endogenous
CD4+ ‘‘help.’’
While the clinical responses in this trial are modest, this
treatment was undertaken in a very heavily pretreated population.
Three of the patients in this protocol had previously received
adoptive T cell targeted therapy on other trials and had
progressed. Median overall survival for all ten patients is
9.7 months. This fares very favorably compared to historical
control of ,4 months for patients with refractory metastatic
melanoma[30]. Three of the nine patients who received both T
cell infusions achieved minor or stable disease lasting 5.8–
11.0 months. Curiously, two patients exhibited delayed disease
stabilization after initial progression and had prolonged survival
for 10.1 and 13.7 months after T cell therapy. This could reflect
delayed immunologic responses and has been observed following
other immunotherapeutic strategies, such as anti-CTLA-4 thera-
py[19]. It may represent early inflammatory response described as
radiographic progression followed by delayed disease responses.
This first study of involving lymphodepletion and CD8+ T cell
clones was designed to limit toxicity of lymphodepletion while
balanced to promote homeostatic cytokines and reduce regulatory
T cells. We acknowledge that higher degrees of lymphodepletion
may increase the availability of homeostatic cytokines and further
reduce regulatory T cells. However, the prolonged CD4
lymphopenia observed with fludarabine may be counterproductive
from the depletion of helper CD4+ cells. Other lymphodepleting
agents, such as cyclophosphamide (when given in high doses),
result in greater, but transient degree of lymphodepletion and may
provide a selective advantage.
Potential opportunities to further improve T cell persistence and
clinical response, include, achieving a greater degree of lymphode-
pletion and enhanced homeostatic cytokine availability with the use
of high dose cyclophosphamide, selective depletion of regulatory
CD4 T cells[31], augmentation with high dose IL-2, and increased
availability of CD4 help. The latter may be achieved through the
transfer of antigen specific CD4+ T cells in tandem with CD8+ T
cell clones to enhance the effector function/proliferative ability of
CD8+ cell, and independently provide anti-tumor activity. Clinical
trials including combination of these elements are currently
underway. In summary, adoptive T cell therapy with CTL clones
is safe and provides a potentially robust instrument for dissectingthe
requirements for a successful T cell strategy. Use of antigen specific
T cell clones remains a viable strategy for treatment of metastatic
melanoma, but further step-wise optimizations to improve T cell
persistence and address regulatory T cells will be important
components in enhancing anti-tumor efficacy.
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